Initial Results of CT-0508 in HER2+ Solid Tumors: Kim A. Reiss Binder, MD

Video

The oncologist from Abramson Cancer Center, Penn Medicine discussed the initial results of the phase 1 trial of CT-0508 in HER2-overexpressing solid tumors.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Kim A. Reiss Binder, MD, medical oncologist, assistant program director, Hematology/Oncology Fellowship Program, Abramson Cancer Center, Penn Medicine, assistant professor of medicine, Hospital of the University of Pennsylvania, about the initial results of a phase 1 trial (NCT04660929) evaluating CT-0508 in patients with HER2-overexpressing solid tumors.

CT-0508 is being evaluated in an ongoing phase 1 trial in patients with HER2-overexpressing solid tumors. The cell therapy is comprised of autologous peripheral blood monocyte–derived macrophages that are transduced with an adenoviral vector containing a HER2-directed CAR and locked into an M1 phenotype.

Initial results of 2 patients treated with CT-0508 were presented during the 2021 SITC Annual Meeting. Regarding safety, 1 patient developed grade 2 cytokine release syndrome (CRS) characterized by fever and hypotension on day 3. The toxicity was resolved on day 4 with acetaminophen (Tylenol), cefepime (Maxipime), and fluids. The other patient, as well as 1 patient who was treated on study but not included in the poster presentation, did not develop CRS with CT-0508.

Although further data are needed to determine whether this therapy is safe, patients treated with CT-0508 are unlikely to develop severe CRS based on the therapy’s mechanism of action, Reiss Binder concludes.

Related Videos
Carlos Moraes, PhD, on Understanding Mitochondrial Mutations for Neurodegenerative Diseases
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
Amar Kelkar, MD, a stem cell transplantation physician at the Dana-Farber Cancer Institute
Frederick “Eric” Arnold, PhD
David Porter, MD
Raj Chovatiya, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.